Johnson & Johnson, Novavax, release positive results from phase 3 trials on their respective coronavirus disease 2019 (COVID-19) vaccines; report indicates undercounted nursing home deaths in New York; experts push for improved mask practices.
Both Johnson & Johnson and Novavax announced positive results of phase 3 trials demonstrating efficacy of each company’s respective coronavirus disease 2019 (COVID-19) vaccine. The single-dose Johnson & Johnson vaccine was found to be 72% effective in the United States and 66% effective overall at preventing moderate to severe COVID-19, 28 days after administration. However, the efficacy rate dropped to 57% in South Africa, where nearly all cases were due to infection with COVID-19 variant B.1.351. In comparison, the Novavax vaccine, which is given in 2 doses, demonstrated 89.3% efficacy in a United Kingdom trial but dropped to 49% in a trial conducted on 4400 volunteers in South Africa. On January 28, the highly transmissible variant B.1.351. was reported for the first time in the United States, in 2 cases in South Carolina.
According to a new state attorney general’s report, the New York State Department of Health undercounted deaths from COVID-19 among nursing home residents by approximately 50%, CNN reports. The findings are based on a survey of 62 nursing homes across the state, accounting for a 10% sample of total facilities in New York. Data suggest the undercount is due to the fact that nursing home residents who died from COVID-19 in hospitals after being transported from nursing homes were not recorded in the department of health’s published data. Underreporting to the department by some nursing homes regarding deaths that occurred in the facilities also appears to have taken place. The New York state health commissioner Howard Zucker, MD, JD, denied there was an undercount in a statement.
In light of new highly transmissible variants of COVID-19 spreading around the globe, experts are pushing for the public to either wear 2 masks or upgrade the quality of single masks to curb transmission, The Washington Post reports. Either putting a second mask on top of one or donning a fabric mask on top of a surgical mask can help better protect against the variants. Some experts recommend buying high-quality KN95 or N95 masks originally reserved for health-care workers. Both Singapore and South Korea have mass-produced high-quality masks to distribute to residents while several European countries have begun mandating medical-grade masks to be worn in public. CDC guidance does not currently call for double masking or using N95s.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More
Health Equity & Access Weekly Roundup: April 14, 2025
April 14th 2025From the potential impact of tariffs to the World Health Organization's year-long campaign launch focused on improving maternal and newborn health and addressing preventable deaths, here's the latest from the Center on Health Equity & Access.
Read More